Solifenacina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Solifenacina" in Italian language version.

refsWebsite

Global rank Italian rank

22nih.gov

4^th place

9^th place

14oadoi.org

799^th place

22^nd place

14doi.org

2^nd place

7^th place

1fda.gov

447^th place

644^th place

doi.org

dx.doi.org

K. Ikeda, S. Kobayashi; M. Suzuki; K. Miyata; M. Takeuchi; T. Yamada; K. Honda, M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland., in Naunyn Schmiedebergs Arch Pharmacol, vol. 366, n. 2, Ago 2002, pp. 97-103, DOI:10.1007/s00210-002-0554-x, PMID 12122494.
SS. Hegde, Muscarinic receptors in the bladder: from basic research to therapeutics., in Br J Pharmacol, 147 Suppl 2, febbraio 2006, pp. S80-7, DOI:10.1038/sj.bjp.0706560, PMID 16465186.
T. Uchida, WJ. Krauwinkel; H. Mulder; RA. Smulders, Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial., in Br J Clin Pharmacol, vol. 58, n. 1, Lug 2004, pp. 4-7, DOI:10.1111/j.1365-2125.2004.02097.x, PMID 15206986.
RA. Smulders, WJ. Krauwinkel; PJ. Swart; M. Huang, Pharmacokinetics and safety of solifenacin succinate in healthy young men., in J Clin Pharmacol, vol. 44, n. 9, settembre 2004, pp. 1023-33, DOI:10.1177/0091270004267592, PMID 15317830.
D. Robinson, L. Cardozo, Solifenacin in the management of the overactive bladder syndrome., in Int J Clin Pract, vol. 59, n. 10, Ott 2005, pp. 1229-36, DOI:10.1111/j.1368-5031.2005.00628.x, PMID 16178992.
M. Maniscalco, D. Singh-Franco; WR. Wolowich; R. Torres-Colón, Solifenacin succinate for the treatment of symptoms of overactive bladder., in Clin Ther, vol. 28, n. 9, Set 2006, pp. 1247-72, DOI:10.1016/j.clinthera.2006.09.017, PMID 17062299.
D. Robinson, L. Cardozo, The emerging role of solifenacin in the treatment of overactive bladder., in Expert Opin Investig Drugs, vol. 13, n. 10, Ott 2004, pp. 1339-48, DOI:10.1517/13543784.13.10.1339, PMID 15461562.
K. Shalders, JE. Gach, Photodistributed lichenoid drug eruption secondary to solifenacin., in Clin Exp Dermatol, vol. 33, n. 3, Mag 2008, pp. 340-1, DOI:10.1111/j.1365-2230.2007.02630.x, PMID 18076676.
N. Warde, Therapy: Solifenacin causes less dry mouth than oxybutynin in OAB., in Nat Rev Urol, vol. 7, n. 6, giugno 2010, p. 303, DOI:10.1038/nrurol.2010.73, PMID 20545037.
N. Pemmaraju, LS. Feldman, Solifenacin-induced small bowel pseudo-obstruction., in J Hosp Med, vol. 3, n. 2, marzo 2008, pp. 176-8, DOI:10.1002/jhm.269, PMID 18438799.
H. Asajima, Y. Sekiguchi; S. Matsushima; N. Saito; T. Saito, QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman., in Br J Clin Pharmacol, vol. 66, n. 6, Dic 2008, pp. 896-7, DOI:10.1111/j.1365-2125.2008.03298.x, PMID 18823303.
PJ. Swart, WJ. Krauwinkel; RA. Smulders; NN. Smith, Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers., in Basic Clin Pharmacol Toxicol, vol. 99, n. 1, luglio 2006, pp. 33-6, DOI:10.1111/j.1742-7843.2006.pto_285.x, PMID 16867168.
ME. Taekema-Roelvink, PJ. Swart; ME. Kuipers; WJ. Krauwinkel; N. Visser; RA. Smulders, Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study., in Clin Ther, vol. 27, n. 9, settembre 2005, pp. 1403-10, DOI:10.1016/j.clinthera.2005.09.002, PMID 16291413.
RA. Smulders, ME. Kuipers; WJ. Krauwinkel, Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects., in Br J Clin Pharmacol, vol. 62, n. 2, Ago 2006, pp. 210-7, DOI:10.1111/j.1365-2125.2006.02638.x, PMID 16842396.

fda.gov

Onyeka Otugo, Olabode Ogundare, Christopher Vaughan, Emmanuel Fadiran, Leyla Sahin, Consistency of Pregnancy Labeling Across Different Therapeutic Classes (PDF), su fda.gov, Food and Drug Administration - Office of Women’s Health, 1979. URL consultato il 27 giugno 2013.

nih.gov

ncbi.nlm.nih.gov

CR. Chapple, P. Araño; JL. Bosch; D. De Ridder; AE. Kramer; AM. Ridder, Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study., in BJU Int, vol. 93, n. 1, gennaio 2004, pp. 71-7, PMID 14678372.
K. Ikeda, S. Kobayashi; M. Suzuki; K. Miyata; M. Takeuchi; T. Yamada; K. Honda, M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland., in Naunyn Schmiedebergs Arch Pharmacol, vol. 366, n. 2, Ago 2002, pp. 97-103, DOI:10.1007/s00210-002-0554-x, PMID 12122494.
T. Fujii, K. Kawashima, YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells., in Gen Pharmacol, vol. 35, n. 2, Ago 2000, pp. 71-5, PMID 11707312.
SS. Hegde, Muscarinic receptors in the bladder: from basic research to therapeutics., in Br J Pharmacol, 147 Suppl 2, febbraio 2006, pp. S80-7, DOI:10.1038/sj.bjp.0706560, PMID 16465186.
ME. Kuipers, WJ. Krauwinkel; H. Mulder; N. Visser, Solifenacin demonstrates high absolute bioavailability in healthy men., in Drugs R D, vol. 5, n. 2, 2004, pp. 73-81, PMID 15293866.
T. Uchida, WJ. Krauwinkel; H. Mulder; RA. Smulders, Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial., in Br J Clin Pharmacol, vol. 58, n. 1, Lug 2004, pp. 4-7, DOI:10.1111/j.1365-2125.2004.02097.x, PMID 15206986.
FJ. Morales-Olivas, L. Estañ, Solifenacin pharmacology., in Arch Esp Urol, vol. 63, n. 1, pp. 43-52, PMID 20157218.
RA. Smulders, WJ. Krauwinkel; PJ. Swart; M. Huang, Pharmacokinetics and safety of solifenacin succinate in healthy young men., in J Clin Pharmacol, vol. 44, n. 9, settembre 2004, pp. 1023-33, DOI:10.1177/0091270004267592, PMID 15317830.
WJ. Krauwinkel, RA. Smulders; H. Mulder; PJ. Swart; ME. Taekema-Roelvink, Effect of age on the pharmacokinetics of solifenacin in men and women., in Int J Clin Pharmacol Ther, vol. 43, n. 5, Mag 2005, pp. 227-38, PMID 15906588.
RA. Smulders, NN. Smith; WJ. Krauwinkel; TJ. Hoon, Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency., in J Pharmacol Sci, vol. 103, n. 1, gennaio 2007, pp. 67-74, PMID 17251687.
D. Simpson, AJ. Wagstaff, Solifenacin in overactive bladder syndrome., in Drugs Aging, vol. 22, n. 12, 2005, pp. 1061-9, PMID 16363887.
D. Robinson, L. Cardozo, Solifenacin in the management of the overactive bladder syndrome., in Int J Clin Pract, vol. 59, n. 10, Ott 2005, pp. 1229-36, DOI:10.1111/j.1368-5031.2005.00628.x, PMID 16178992.
M. Maniscalco, D. Singh-Franco; WR. Wolowich; R. Torres-Colón, Solifenacin succinate for the treatment of symptoms of overactive bladder., in Clin Ther, vol. 28, n. 9, Set 2006, pp. 1247-72, DOI:10.1016/j.clinthera.2006.09.017, PMID 17062299.
D. Robinson, L. Cardozo, The emerging role of solifenacin in the treatment of overactive bladder., in Expert Opin Investig Drugs, vol. 13, n. 10, Ott 2004, pp. 1339-48, DOI:10.1517/13543784.13.10.1339, PMID 15461562.
K. Shalders, JE. Gach, Photodistributed lichenoid drug eruption secondary to solifenacin., in Clin Exp Dermatol, vol. 33, n. 3, Mag 2008, pp. 340-1, DOI:10.1111/j.1365-2230.2007.02630.x, PMID 18076676.
N. Warde, Therapy: Solifenacin causes less dry mouth than oxybutynin in OAB., in Nat Rev Urol, vol. 7, n. 6, giugno 2010, p. 303, DOI:10.1038/nrurol.2010.73, PMID 20545037.
N. Pemmaraju, LS. Feldman, Solifenacin-induced small bowel pseudo-obstruction., in J Hosp Med, vol. 3, n. 2, marzo 2008, pp. 176-8, DOI:10.1002/jhm.269, PMID 18438799.
H. Asajima, Y. Sekiguchi; S. Matsushima; N. Saito; T. Saito, QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman., in Br J Clin Pharmacol, vol. 66, n. 6, Dic 2008, pp. 896-7, DOI:10.1111/j.1365-2125.2008.03298.x, PMID 18823303.
R. Sannerstedt, P. Lundborg; BR. Danielsson; I. Kihlström; G. Alván; B. Prame; E. Ridley, Drugs during pregnancy: an issue of risk classification and information to prescribers., in Drug Saf, vol. 14, n. 2, febbraio 1996, pp. 69-77, PMID 8852521.
PJ. Swart, WJ. Krauwinkel; RA. Smulders; NN. Smith, Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers., in Basic Clin Pharmacol Toxicol, vol. 99, n. 1, luglio 2006, pp. 33-6, DOI:10.1111/j.1742-7843.2006.pto_285.x, PMID 16867168.
ME. Taekema-Roelvink, PJ. Swart; ME. Kuipers; WJ. Krauwinkel; N. Visser; RA. Smulders, Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study., in Clin Ther, vol. 27, n. 9, settembre 2005, pp. 1403-10, DOI:10.1016/j.clinthera.2005.09.002, PMID 16291413.
RA. Smulders, ME. Kuipers; WJ. Krauwinkel, Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects., in Br J Clin Pharmacol, vol. 62, n. 2, Ago 2006, pp. 210-7, DOI:10.1111/j.1365-2125.2006.02638.x, PMID 16842396.

oadoi.org

K. Ikeda, S. Kobayashi; M. Suzuki; K. Miyata; M. Takeuchi; T. Yamada; K. Honda, M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland., in Naunyn Schmiedebergs Arch Pharmacol, vol. 366, n. 2, Ago 2002, pp. 97-103, DOI:10.1007/s00210-002-0554-x, PMID 12122494.
SS. Hegde, Muscarinic receptors in the bladder: from basic research to therapeutics., in Br J Pharmacol, 147 Suppl 2, febbraio 2006, pp. S80-7, DOI:10.1038/sj.bjp.0706560, PMID 16465186.
T. Uchida, WJ. Krauwinkel; H. Mulder; RA. Smulders, Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial., in Br J Clin Pharmacol, vol. 58, n. 1, Lug 2004, pp. 4-7, DOI:10.1111/j.1365-2125.2004.02097.x, PMID 15206986.
RA. Smulders, WJ. Krauwinkel; PJ. Swart; M. Huang, Pharmacokinetics and safety of solifenacin succinate in healthy young men., in J Clin Pharmacol, vol. 44, n. 9, settembre 2004, pp. 1023-33, DOI:10.1177/0091270004267592, PMID 15317830.
D. Robinson, L. Cardozo, Solifenacin in the management of the overactive bladder syndrome., in Int J Clin Pract, vol. 59, n. 10, Ott 2005, pp. 1229-36, DOI:10.1111/j.1368-5031.2005.00628.x, PMID 16178992.
M. Maniscalco, D. Singh-Franco; WR. Wolowich; R. Torres-Colón, Solifenacin succinate for the treatment of symptoms of overactive bladder., in Clin Ther, vol. 28, n. 9, Set 2006, pp. 1247-72, DOI:10.1016/j.clinthera.2006.09.017, PMID 17062299.
D. Robinson, L. Cardozo, The emerging role of solifenacin in the treatment of overactive bladder., in Expert Opin Investig Drugs, vol. 13, n. 10, Ott 2004, pp. 1339-48, DOI:10.1517/13543784.13.10.1339, PMID 15461562.
K. Shalders, JE. Gach, Photodistributed lichenoid drug eruption secondary to solifenacin., in Clin Exp Dermatol, vol. 33, n. 3, Mag 2008, pp. 340-1, DOI:10.1111/j.1365-2230.2007.02630.x, PMID 18076676.
N. Warde, Therapy: Solifenacin causes less dry mouth than oxybutynin in OAB., in Nat Rev Urol, vol. 7, n. 6, giugno 2010, p. 303, DOI:10.1038/nrurol.2010.73, PMID 20545037.
N. Pemmaraju, LS. Feldman, Solifenacin-induced small bowel pseudo-obstruction., in J Hosp Med, vol. 3, n. 2, marzo 2008, pp. 176-8, DOI:10.1002/jhm.269, PMID 18438799.
H. Asajima, Y. Sekiguchi; S. Matsushima; N. Saito; T. Saito, QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman., in Br J Clin Pharmacol, vol. 66, n. 6, Dic 2008, pp. 896-7, DOI:10.1111/j.1365-2125.2008.03298.x, PMID 18823303.
PJ. Swart, WJ. Krauwinkel; RA. Smulders; NN. Smith, Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers., in Basic Clin Pharmacol Toxicol, vol. 99, n. 1, luglio 2006, pp. 33-6, DOI:10.1111/j.1742-7843.2006.pto_285.x, PMID 16867168.
ME. Taekema-Roelvink, PJ. Swart; ME. Kuipers; WJ. Krauwinkel; N. Visser; RA. Smulders, Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study., in Clin Ther, vol. 27, n. 9, settembre 2005, pp. 1403-10, DOI:10.1016/j.clinthera.2005.09.002, PMID 16291413.
RA. Smulders, ME. Kuipers; WJ. Krauwinkel, Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects., in Br J Clin Pharmacol, vol. 62, n. 2, Ago 2006, pp. 210-7, DOI:10.1111/j.1365-2125.2006.02638.x, PMID 16842396.